Catalog No.
VHJ64001
Species reactivity
Human
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
SLAMF7, CRACC, Protein 19A, SLAM family member 7, CD2-like receptor-activating cytotoxic cells, Membrane protein FOAP-12, CD319, Novel Ly9, CD2 subset 1, CS1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NQ25
Applications
ELISA, Neutralization, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0264
The multifaceted role of CS1 (SLAMF7) in immunoregulation: Implications for cancer therapy and autoimmune disorders., PMID:40073958
Elotuzumab-mediated ADCC with Th1-like Vγ9Vδ2 T cells to disrupt myeloma-osteoclast interaction., PMID:39557586
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide., PMID:39054911
Beyond BCMA: newer immune targets in myeloma., PMID:38865708
Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity., PMID:38819238
Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization., PMID:38720898
Targeted therapy for multiple myeloma: an overview on CD138-based strategies., PMID:38655136
Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy., PMID:38484085
SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments., PMID:37754488
Identification and elucidation of cross talk between SLAM Family Member 7 (SLAMF7) and Toll-like receptor (TLR) pathways in monocytes and macrophages., PMID:37420084
Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells., PMID:35262781
[Bispecific antibodies in multiple myeloma]., PMID:34920804
Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma., PMID:34680541
Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials., PMID:34488679
[The Significance of CD319 and CD269 in the Detection of Immunophenotyping and Minimal Residual Disease in Multiple Myeloma Patients]., PMID:34362502
Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE., PMID:33828555
Antibody treatment in multiple myeloma., PMID:33739965
Selective elimination of immunosuppressive T cells in patients with multiple myeloma., PMID:33597728
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns., PMID:33575947
A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients., PMID:33507526
Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments., PMID:33420283
Current antibody-based therapies for the treatment of multiple myeloma., PMID:33406065
CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab., PMID:33017079
Toward further simplification of elotuzumab therapy by subcutaneous administration., PMID:32656639
Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer., PMID:32630303
Association of circulating SLAMF7+Tfh1 cells with IgG4 levels in patients with IgG4-related disease., PMID:32487061
Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy., PMID:32398792
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma., PMID:31969330
Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma., PMID:31898440
Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma., PMID:31650133
Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide., PMID:31566043
Editorial: Immunotherapy in Multiple Myeloma., PMID:31475006
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma., PMID:31431433
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7., PMID:31358854
Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab., PMID:31270105
Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy., PMID:31164030
Novel targets for the treatment of relapsing multiple myeloma., PMID:31125526
Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma., PMID:31115879
Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis., PMID:30710089
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma., PMID:30455698
Clinical impact of serum soluble SLAMF7 in multiple myeloma., PMID:30410677
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy., PMID:30147690
SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target., PMID:29785767
A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma., PMID:29769244
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy., PMID:29582696
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)., PMID:29572070
Impact of chronic blood viral infection on lymphocyte telomere length in Chornobyl clean-up workers in a remote period after radiation exposure., PMID:29286521
Mechanisms of Action and Clinical Development of Elotuzumab., PMID:29272564
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes., PMID:29089311
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms., PMID:28932638
For research use only. Not for human or drug use.
